Björn Frendéus (Former)
1 – 7 of 7
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Phase 1/2a clinical trial of BI-1206, an anti-CD32b (FcγRIIB) antibody, in combination with pembrolizumab in subjects with advanced solid tumors previously treated with anti-PD-1/PD-L1.
- Contribution to journal › Scientific review
-
Mark
19-BI-1808-01, a phase 1/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter with or without pembrolizumab.
- Contribution to journal › Scientific review
- 2021
-
Mark
Accelerating target deconvolution for therapeutic antibody candidates using highly parallelized genome editing
- Contribution to journal › Article
- 2019
-
Mark
Deep mining of complex antibody phage pools generated by cell panning enables discovery of rare antibodies binding new targets and epitopes
- Contribution to journal › Article
- 2018
-
Mark
A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia
- Contribution to journal › Article
-
Mark
Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function
- Contribution to journal › Article
- 2001
-
Mark
Role of Neutrophils and Innate Immune Mechanisms in Urinary Tract Infections
(2001)
- Thesis › Doctoral thesis (compilation)
